Complications ophtalmologiques du traitement de l’hépatite C

Sauer, Arnaud; Lenoble, P.; Bader, Pia; Speeg-Schatz, C.; Bourcier, Tristan; Nasica, X.

doi:10.1016/s0181-5512(07)91366-2

Journal Français d'Ophtalmologie

2007

DOI: 10.1016/s0181-5512(07)91366-2

|View full text |Cite

Complications ophtalmologiques du traitement de l’hépatite C

Arnaud Sauer

P. Lenoble

Pia Bader

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2015

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other documented ocular complications of interferon alpha therapy include transient blurred vision (20), increased intraocular pressure (21), neovascular glaucoma (22), retinal detachment (5), and orbital and intraocular hemorrhage leading to enucleation (21,23). Nonarteritic anterior ischemic optic neuropathy (NAION) is a relatively rarely reported complication of interferon alpha therapy (15,24–40). …”

mentioning

confidence: 99%

Pegylated Interferon Alpha-Associated Optic Neuropathy

Berg

Nelson

Harrison

et al. 2010

Journal of Neuro-Ophthalmology

View full text Add to dashboard Cite

A 52-year-old man with chronic hepatitis C presented with painless, bilateral, simultaneous non-arteritic anterior ischemic optic neuropathy (NAION) and peripheral neuropathy. Symptoms began 19 weeks after starting peginterferon alpha-2a. The peripheral neuropathy and vision of the right eye improved, but the vision of the left eye worsened after stopping interferon. We identified 23 additional cases of NAION during interferon alpha therapy. At least 12 of these patients suffered bilateral NAION. Patients lost vision 1–40 weeks after initiating therapy. Of 21 eyes that had documented initial and follow-up acuities, 8 improved, 1 worsened, and the rest remained stable. One patient had a painful peripheral neuropathy. Treatment with interferon alpha may result in NAION. Discontinuation of therapy deserves consideration after weighing individual risks and benefits.

show abstract

mentioning

confidence: 99%

Pegylated Interferon Alpha-Associated Optic Neuropathy

Berg

Nelson

Harrison

et al. 2010

Journal of Neuro-Ophthalmology

View full text Add to dashboard Cite

show abstract

Rétinopathie à interferon pégylé alpha 2a et ribavirine au cours d’une hépatite virale C chronique

Ngatcha

Rouibaa

Majdouli

et al. 2012

J Afr Hepato Gastroenterol

View full text Add to dashboard Cite

Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitisC

Kabbaj

Sentissi

Mohammadi

et al. 2009

Gastroentérologie Clinique et Biologique

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Complications ophtalmologiques du traitement de l’hépatite C

Cited by 6 publications

References 19 publications

Pegylated Interferon Alpha-Associated Optic Neuropathy

Pegylated Interferon Alpha-Associated Optic Neuropathy

Rétinopathie à interferon pégylé alpha 2a et ribavirine au cours d’une hépatite virale C chronique

Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitisC

Contact Info

Product

Resources

About